CTRI Confirms Leading Indian CRO Supports Majority of Hemophilia Trials in India

Max Neeman International is the only CRO in India to manage hemophilia trials according to the Clinical Trials Registry-India (CTRI). Of the total hemophilia trials currently being conducted in India, Max Neeman can boast supporting 80% of these with the remaining conducted by pharma companies.

Max Neeman International has established a team of experts specialized in carrying out hemophilia trials in response to sponsor demand. The team has the required expertise via involvement of academia with industry, hemophilia trial experience and extensive database of best Investigators for indication to develop innovative approaches to optimize complex study design. Often strict inclusion/exclusion criteria and data analysis for such studies create the greatest challenge for Biotech and Pharma that the company's expertise can address.

Max Neeman is a leading CRO in India that has a focus on hemophilia and bleeding disorder studies, in addition to other indications. Patient enrollment for complex global and multi-centric hemophilia trials is challenging because potential subjects are fewer in number and widely dispersed. With an Incidence of 1 in 10,000 people, India has more than 120,000 hemophilic and thus it has evolved into a preferred destination for conducting such trials because of low cost and faster patient recruitment.

Source: PRNewswire

Comments

ICH GCP requires EC members to be independent of investigator and sponsor to avoid conflicts of interest

Can an Ethics Committee member e.g. layman/chairman or anyone in the committee participate in the trial as a subject? Vidya If an Ethics Committee member becomes a trial subject on a trial that he/she was involved in approving then there has been a major conflict of interest. The following situations need to be considered: ● IEC member reviews study without any prior knowledge of the study, votes, and then afterwards is approached by clinical research team to participate. Possibly this is OK but the member should no longer be part of the IEC that reviews that study. This will be difficult in practice, so therefore it is not advisable. ● IEC member already knows about the study and is voting in order to be able to participate. This is clearly not acceptable and made worse if there is additional financial incentive for the study (e.g. volunteer study). ICH GCP requires Ethics Committee members to be independent of the investigator and the sponsor to avoid confl...

Indian government outlines policies on drug pricing to favor poorer patients, and increase clinical trials

The Indian government is looking to review the existing drug price control measures in order to make medicines more affordable in the country, and at increasing the number of clinical trials taking place in the country, reports The Pharma Letter's India correspondent. In a parallel move, the Health Ministry is also preparing a framework for public private partnership to tackle the menace of non-communicable diseases in the country, In a move that could potentially result in affordable Medicare and health security moving to a larger section of the population, the government is considering a rash of policy measures in favor of poor patients. Talks are also on in government circles to abolish clinical trials on proven drugs that have been approved and marketed for at least two years in the European Union, United States, UK, Australia, Canada and Japan. A draft proposal in this regard has been prepared by the Health Ministry. If instituted, it would reduce the time taken to introduce n...

How drugs work

Prescription Drugs Special Report Ever wonder how the medications you take act in your body? This brief guide explains how several classes of popular drugs work. Thousands of medications are in use today. Here are some of the most common mechanisms by which these drugs achieve their effects: Antibiotic Drugs -- The development of safe and effective drugs to cure infections was arguably the most significant advance in drug development of the 20th century. Perhaps the most famous example is penicillin, which is derived from a toxin produced by the fungus Penicillium notatum that contaminated a laboratory experiment. The Scottish scientist Alexander Fleming noticed that the Penicillium fungus had done something to kill the bacterium Staphylococcus, which is responsible for many human infections. Antibiotics have several modes of action. Penicillin disrupts the cell walls of bacteria, causing them to die. Some other antibiotics interfere with the ability of microorganisms to ...

My Clinical Trials Diary

Search This Blog